Next Phase Newsletter

The healthcare system operates 80+ hospitals across Asia, the Middle East and Turkey. The firm has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The fund only invests in the digital health space. The firm is interested in many areas of digital health, diagnostics, and tech-enabled healthcare services, including wellness, digital therapeutics, AI, healthcare data, remote monitoring, chronic disease management, etc. The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm was founded in 1999 and has offices in the Southeast and Midwest US. The firm has three funds under management. The fund typically makes investments of $2-5 million, and also considers participating in larger syndicated rounds. The firm considers minority and control equity positions as well as subordinated debt. The firm invests throughout the USA. The firm prefers to lead or co-lead investment rounds.

The firm is focused on products or services within the health and wellness space. In addition to wellness-oriented products and services, the firm is also interested in opportunities in the digital health, medical technology, healthcare IT, healthcare services, and biotech lab equipment sectors. The fund’s previous life science investments include surgical devices and instrumentation.

The firm invests in second-stage companies approaching $5 million in revenue. The firm has a focus on companies led by women or which target female consumers, though this is not a requirement for investment. In the medical device sector, the firm only invests in companies with products approved by the FDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, the firm has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. The firm has received three NDA approvals, including two in mainland China and one in Taiwan, and multiple late-stage candidates are in pivotal trials or registrational stages. The firm’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. The company is currently seeking in-licensing, out-licensing and partnership opportunities globally.

The firm is particularly interested in first-in-class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy and gene therapy. The firm is interested in opportunities for both greater China as well as global market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2011 and based is Dallas, Taxas, the firm is focused on healthcare companies and makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A healthcare venture capital investment firm was founded in 2001 and is based in Boston, Massachusetts. The firm currently manages over $450 million, including their recently announced $255 million second healthcare IT and services focused venture fund in July 2019. The firm generally makes investments in early stage companies targeting healthcare technology and services. The investment size will vary, depending on the opportunity. The firm typically invests in companies based in the United States though is open to companies based on a global level.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and tech-enabled services sectors with a specific focus on payment reform, patients as consumers, healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare. The firm currently is not focused on therapeutics or traditional medical device investment opportunities, though may consider medical devices with a software/data component, such as sensors, that have either already obtained FDA clearance or are not subject to FDA regulation. The firm is indication agnostic and invests in pre-revenue to growth stage products.

The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Based in Oklahoma City, an investment firm previously in the energy and oil space, and in the last year has expanded their interests to begin investing in the life science space as well. The firm is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and digital health sectors. The firm invests in Seed, Series A and B and is willing to both lead or participate in the investments. The firm is opportunistic in terms of sub-sectors and indications including all phases of development for therapeutics. Since starting to invest in the biotech space last fall, the firm currently has made 5 investments. The typical check size ranges from $500K up to $6M depending on the company and syndicate. The firm focuses on companies located in the United States.

The firm is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and digital health sectors. The firm is opportunistic in terms of sub-sectors and indications, including 510K and PMA classes of medical devices, as well as all phases of development for therapeutics including pre-clinical companies. The firm is also open to looking at pre-prototype companies on a case by case basis

The firm looks for a management team with a proven track record and strong sector knowledge and experience. The firm looks for companies who have done regulatory submission and successful exits as well. The firm is open to both leading or coinvesting in the investment and seeks board seat representation when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A corporate venture capital arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the parent company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the parent company’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.